Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Diabetic Screening Performed in Dental Setting

By LabMedica International staff writers
Posted on 01 Mar 2012
Oral blood samples drawn from deep pockets of periodontal inflammation can be used to measure glycated hemoglobin (HbA1c) an important gauge of a patient's diabetes status. More...


HbA1c is widely used to test for diabetes and blood glucose measured from oral blood compare well to those from finger-stick blood where an HbA1c reading of 6.5% or more indicates a value in the diabetic range.

At the New York University (NY, USA) a nursing and dental team of scientists compared HbA1c levels in paired samples of oral gingival crevicular blood (GCB) and finger-stick blood (FSB) taken from patients with periodontal disease. The oral blood was from patients with adequate bleeding on probing and was collected on special blood collection cards.

The blood samples were analyzed for HbA1c using the BioRad Variant II Analyzer (BioRad; Hercules, CA, USA), which employs high-performance liquid chromatography, and exclusively uses BioRad Reagents. A total of 120 individuals were eligible and participated in the study and provided a FSB sample for HbA1c testing. Average FSB HbA1c readings were 6.0% ± 0.83% with 20 in the diabetes range. An additional 66 patients had FSB HbA1c test results in the prediabetes range, which is between 5.7% and 6.4%, and are at increased risk of developing diabetes in the future.

Oral blood samples were also collected from 102 of the 120 participants; no bleeding on probing or insufficient bleeding to cover adequately the tip of the blood collection wand prevented collection and/or laboratory analysis of GCB samples from the remaining 18 participants. In the case of 27 of the 102 GCB samples, an unidentified component was observed to co-elute within the elution window of HbA1c in the laboratory. The presence of a co-elution peak from this unidentified component interfered with the quantification of HbA1c and generally resulted in underestimation of true HbA1c percentages. Therefore, only 75 patients' blood samples could be compared with both tests.

Of these 75 participants, 15 had FSB HbA1c values in the diabetes range of equal to or greater than 6.5%, including 8 who indicated that they had never been told by a health care provider that they had diabetes. For these 75 participants, the correlation between FSB and GCB HbA1c values was very high. Sheila M. Strauss, PhD, the principal author said, "In light of these findings, the dental visit could be a useful opportunity to conduct an initial diabetes screening, an important first step in identifying those patients who need further testing to determine their diabetes status". The study was published online on November 16, 2011 in the Journal of Periodontology.

Related Links:

New York University
BioRad



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.